Assembly Biosciences (ASMB) Prices 5.15M Share Common Offering at $16.50/Sh
Get Alerts ASMB Hot Sheet
Join SI Premium – FREE
Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced the pricing of an underwritten public offering of 5,151,515 shares of its common stock to the public at $16.50 per share. In addition, and in lieu of common stock, Assembly is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2,424,242 shares of common stock at a purchase price of $16.499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The offering is expected to close on or about December 16, 2019, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to Assembly from this offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Assembly. Assembly has granted the underwriters a 30-day option to purchase up to an additional 1,136,363 shares of common stock at the offering price, less the underwriting discounts and commissions. Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.
Jefferies LLC, SVB Leerink LLC and William Blair & Company, L.L.C. are acting as joint bookrunning managers for the offering. Mizuho Securities USA LLC and Robert W. Baird & Co. Incorporated are acting as co-managers for the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alto Neuroscience prices $100M stock offering to fund depression trial
- Mercedes-Benz USA Reports 84,500 Retail Sales in Q2 2026
- Tailored Brands files for IPO on Nasdaq
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
William Blair, Jefferies & Co, Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share